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Abstract 
 Regular formation of the mammalian heart needs precise spatial and temporal 
transcriptional regulation of gene programs in cardiomyocytes. Cardiac transcription factors are 
defined, in this context, as essential transcriptional activators that are expressed predominantly 
in the myocardium which regulate the expression of the cardiac genes encoding structural 
proteins of cardiomyocytes. Unsurprisingly, disruptions in this elaborate transcriptional 
machinery can lead to severe cardiac abnormalities including hypertension, cardiomyopathy, and 
congenital heart disease. In this field, Myocyte Enhancer Factor 2 (MEF2) transcription factor is 
considered one of only a few core cardiac transcription factors that play important roles in 
cardiac development, survival, contractility, and in postnatal adaption to a wide array of 
physiological and pathological signals. 
 MEF2 functions as a transcriptional switch by potently activating or repressing 
transcription through interaction with a variety of co-factors which serve as positive and negative 
regulators of transcription. The interaction of MEF2 with its co-factors is controlled by a 
multitude of signaling pathways that result in post-translational modification of MEF2 and in the 
subsequent MEF2-dependent repression or activation of target gene transcription. Our project 
studied regulation and function of MEF2A in cardiomyocytes. We hypothesized that the 
combinatorial interactions between transcription factors and promoter elements that are 
required for the regulation of cardiac gene expression may operate in pathological cardiac 
remodeling and hypertrophy. Therefore, studying and characterizing the regulation of proteins 
which bind to MEF2A in cardiomyocytes may unravel the underlying dysregulation of the cardiac 
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transcriptome in the pathogenesis of cardiovascular disease and heart failure. In this project, HL-
1 cardiomyocytes have been chosen as a model of study. An agonist (Isoproterenol) was used to 
mimic cardiomyocytes hypertrophy in HL-1 cells. Isoproterenol activates adrenergic signaling 
which can trigger many mechanisms in the heart contributing to the hypertrophic phenotype. 
We developed two different methods to capture MEF2A interacting partners (interactome), 
including immunoprecipitation (IP) of endogenous MEF2A and IP of Flag-MEF2A proteins in 
normal and hypertrophy conditions. Our optimization will allow characterization of MEF2A 
interactome partners through state of the art quantitative proteomics approaches.  
 In previous research, transcriptome analysis (RNA-seq) from left ventricular RNA samples 
and MEF2A depleted cardiomyocytes identified some genes, including kf2, junb, alas2 and 
rarres2 which may have implications in cardiac hypertrophy. Our ChIP-qPCR data indicated that 
MEF2A is recruited to the rarres2 promoter in primary cardiomyocytes. Thus, rarres2 is a novel 
MEF2A target gene and further, it will be interesting to uncover functions of MEF2A interactome 
partners on rarres2 gene regulation in cardiac diseases. A study has indicated that klf2, junB, 
alas2, and rarres2 may have a role in promoting cardiomyocyte hypertrophy in cultured HL-1 cells 
and primary neonatal rat cardiomyocytes. Taken together, this project developed the methods 
to study characterization of MEF2A interactome in cardiomyocytes. Additionally, we showed the 
capacity of some MEF2 target genes, including rarres2 to promote cardiomyocyte hypertrophy.  
 
 
 
 
IV 
 
ACKNOWLEDGEMENTS 
 
I cannot tell how much I appreciate my family to support and give me positive energy to pursue 
my goals in life especially when we lost Dad. Thank you, Mom, for everything you have done for 
me my entire life. There is no way for me to express my utmost gratitude and thanks to you too. 
Through, the good times and the bad, you have always been there for me guiding me on the right 
path. 
I also take this opportunity to express my sincere appreciation to Dr. McDermott for giving me 
this great chance for learning so many things about science and research in such a short time. I 
am very grateful for being part of your team and for receiving mentorship from you since the first 
day at York University. I would also like to thank my committee, Dr. Robert Tsushima for his 
guidance and thoughtfulness. I will surely miss short informative conversations which I had with 
you sometimes.  
I would like to thank my great lab members. Thank you guys for your support and criticism. In 
particular, I would like to thank Stephanie and Sara for training me from the beginning. Ali, 
Michael, and Vijay for energy enthusiasm. It was great to work with you guys.  
 
 
 
 
 
V 
 
TABLE OF CONTENTS 
 
ABSTRACT .................................................................................................................................................... II 
ACKNOWLEDGMENTS .............................................................................................................................. IV 
TABLE of CONTENTS  ................................................................................................................................. V 
LIST of FIGURES ........................................................................................................................................ VII 
LIST of ABBREVATIONS  ........................................................................................................................ VIII 
INTRODUCTION  ......................................................................................................................................... 1 
1. General overview  ........................................................................................................................ 1 
2. MEF2 role and regulation  ............................................................................................................ 2 
2.1 MEF2 overview ............................................................................................................. 2 
2.2 The structure of MEF2 family proteins  ........................................................................ 3 
2.3 MEF2 isoforms and their function in the heart  ........................................................... 5 
2.4 Regulation of MEF2 activity by post-translational modifications  ................................ 6 
2.4.1 MEF2 functions as a transcriptional co-factors  ........................................... 6 
2.4.2 MEF2 and chromatin remodeling  ............................................................... 7 
2.4.3 MEF2 regulation upon signaling pathways in cardiomyocytes  ................... 9 
3. Myocardial remodeling  ............................................................................................................. 11 
3.1 Cardiac hypertrophy ................................................................................................ 12 
VI 
 
3.2 Signaling pathways in cardiac hypertrophy  ............................................................... 14 
3.2.1 Myocardial G-protein-Coupled Receptors (GPCRs) ................................... 14 
3.2.2 Ca2+ / calcineurin / NFAT / and Ca2+ / CaMKII  ............................................ 16 
3.2.3 MEF2 / Histone Deacetylases (HDACs)  ..................................................... 17 
STATEMENT of PURPOSE  ....................................................................................................................... 18 
RATIONALE of STUDY  ............................................................................................................................. 19 
MATERIALS and METHODS  ................................................................................................................... 22 
RESULTS  .................................................................................................................................................... 32 
DISCUSSION  ............................................................................................................................................. 42 
FUTURE DIRECTIONS ............................................................................................................................... 48 
REFERENCES .............................................................................................................................................. 50 
 
 
 
 
 
 
 
VII 
 
LIST of FIGUERS 
1. Schematic diagrams of MEF2 isoforms 
2. MEF2 functions as a signal dependent transcriptional switch 
3. MEF2 regulation upon signaling pathways in cradiomyocytes 
4. Different types of cardiac hypertrophy 
5. Regulation of MEF2 by GPCRs (β-Adrenergic Receptos) 
6. Immunoprecipitation of endogenous MEF2A interactome in cardiomyocytes  
7. Immunoprecipitation of 3X-Flag-MEF2A in cardiomyocytes 
8. Using Isoproterenol to mimic cardiac hypertrophy in HL-1 cardiomyocytes 
9. Immunoprecipitation of endogenous MEF2A interactome in cardiomyocytes 
hypertrophy 
10. Potential role of junb, klf2, and alas2 genes to induce cardiomyocytes hypertrophy 
11. ChIP-qPCR analysis 
12. Potential role of rarres2 gene to promote cardiomyocytes hypertrophy 
 
 
 
 
 
 
 
VIII 
 
LIST of ABBREVATION 
Mef2   Myocyte Enhancer Factor-2  
GATA4   GATA Binding Protein 4 
Tbx5  T-box Transcription factor TBX5 
NFAT   Nuclear Factor of Activated T-cell 
HATs   Histone Acetylates 
HDACs   Histone Deacetylases 
bHLH  basic helix-loop-helix 
MAPK   Mitogen-Activated Protein Kinases 5 
GPCRs   G-Protein Coupled Receptors 
βAR   β-Adrenergic Receptors 
CaMK   calcium / calmodulin-dependent kinase 
SERCA   Sarcoplasmic Reticulum Ca2+ ATAPase 
MyHC   Myosin Heavy Chain 
ANF   Atrial Natriuretic Factor 
Klf2   Kruppel like factor 2 
Rarres2  Retinoic Acid Receptor Responder Protein 2 
Alas2   delta-aminolevolinic acid synthase 2 
PKA   Protein Kinase A 
IX 
 
PKC   Protein Kinase C 
TAD   Transcriptional Activation Domain 
MADS   Mcm1 Agamous Deficiens Srf 
cAMP   Cyclic Adenosine Monophophate 
ISO   Isoproterenol 
Ate   Atenolol  
TAC   Transverse Aortic Constriction  
HF  Heart Failure  
MLC1/3 myosin light chain 1/3 
MLC2v  ventricular myosin light chain 2 
GLUT4  insulin-sensitive glucose transporter 4 
ET-1  endothelin I 
AngII  angiotensin II 
PLC  phospholipase C 
CO  cardiac output 
IP  immunoprecipitation 
WGA  wheat germ agglutinin  
MMPs  matrix metalloproteinase 
Junb  Jun-B proto-oncogene 
X 
 
WB  western blot 
SRF  serum response factor 
GATA4  GATA binding protein 4 
Nkx2-5  NK2 transcription factor related, locus 5 
RT-PCR  Reverse transcription polymerase chain reaction 
Q-PCR  Quantitative polymerase chain reaction 
ChIP  Chromatin immunoprecipitation 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
1 
 
Literature Review, 
1. General Overview 
 Regulation of gene expression is fundamental in cell growth, differentiation, and disease. 
Signal-dependent on gene regulation is modulated by transcription factors. Transcription factors 
are a very different family of proteins and generally function in multi-subunit protein complexes. 
They may bind to the specific DNA sequences such as promoter and enhancer to regulate turn 
off or turn on genes (1). Cardiac transcription factors govern the complex process of heart 
development during embryogenesis and cardiogenesis and are involved in stress regulation of 
the adult heart in response to hypertrophic stimulation in the generation of cardiac hypertrophy 
or cardiac protection from cytotoxic stress. Pathological heart diseases activate pathological 
signaling pathways that target transcription factors and reprogram cardiac gene expression, 
which then translated into the production of proteins involved in cardiac hypertrophy, leading to 
heart failure (2). Thus, the regulation of a network of transcriptional regulatory proteins in the 
heart has indeed been a central theme in understanding the molecular control of physiology and 
pathology of the heart. A number of transcriptional regulators such as the GATA family, Myocyte 
Enhancer Factor 2 (MEF2), the home box transcription factor CSX/NKX 2-5, and nuclear factor of 
activated T-cell (NFAT). They have been identified as playing prominent roles in the heart via 
control of cardiac gene expression particularly MEF2 as a core transcription factor involved in 
cardiac physiological and pathological pathways (3). 
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2. MEF2 role and regulation 
2.1 MEF2 Overview 
 MEF2 transcription factors have prominent roles in cell differentiation, proliferation, 
apoptosis, migration, shape, and metabolism in cardiac muscle, skeletal muscle, vascular, neural, 
blood and immune system (4). MEF2 family factors belong to the MADS (Mcm1, Agamous, 
Deficiens, Serum response factor) superfamily of sequence-specific DNA-binding transcription 
factors (5). They were initially identified as a prominent factor in skeletal muscle development 
that can bind A/T-rich sequence within gene promoter of muscle creatine kinase (mck). These 
MEF2 dependent genes can encode a wide array of proteins, including structural proteins like α-
cardiac myosin heavy chain (α-MHC), myosin light chain 1/3 (MLC1/3), ventricular myosin light 
chain 2 (MLC2v), sarcoplasmic reticulum Ca2+ ATPase (SERCA), cardiac troponin (-T,-C, and –I), 
desmin, dystrophin and insulin-sensitive glucose transporter 4 (GLUT4) which regulate cardiac 
metabolism (6).  
 Vertebrate MEF2 is encoded by four genes, mef2a, -b, -c, and –d, that are expressed in 
cardiac muscle. These proteins play predominant roles in the differentiation, morphogenesis, and 
maintenance of vertebrate tissue types. MEF2 proteins contain three domains: an N-terminal 
DNA-binding MADS domain, a central MEF2 domain and a C-terminal transactivation domain. 
The MADS and MEF2 domains are well conserved among MEF2 family proteins, unlike the 
transactivation domain which is divergent across MEF2 proteins (5).  
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2.2 The structure of MEF2 family proteins 
 MEF2 family proteins from different species share similar N-terminal that contains a 
highly conserved MADS-box domain and an immediate adjacent MEF2 domain, it consists of 58-
amino acids MADS domain and an adjacent 28 amino-acids MEF2 domain. This region plays a key 
role in the recognition of their target sequences. The main roles of these invariable residues are 
combined with abundant A/T DNA sequences and they regulate dimerization of MADS-box 
proteins and provide places for the interaction of MEF2 with other co-factors. Due to the 
conserved sequence within MEF2 domain, MEF2A, B, C, and D can form homodimers or 
heterodimers structures with themselves or hetero-dimerization with other molecules (5). 
Collectively, these two domains mediate dimerization, co-factor interactions and DNA binding to 
the consensus DNA sequence (T/C) TA (A/T)4 TA(G/A). MEF2 from C-terminal has conserved 
regions containing potential phosphorylation sites recognized by some kinases, however, the 
remainder is less conserved (7) (8).  
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Figure 1. Schematic diagrams of MEF2 isoforms. MEF2 family proteins, including MEF2A, B, C, 
and D share a similar N-terminal containing a highly conserved MADS-box domain and immediate 
adjacent MEF2 domain. Both domains contribute to DNA binding and dimerization. However, 
there is a diversity in the structure of transactivation domain of MEF2 family members in C-
terminal along with the number of amino acids in the longer form of each protein.  
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2.3 MEF2 isoforms and their function in the heart    
 In the heart, MEF2 family proteins have been recognized as prominent regulators to 
control cardiac muscle differentiation, vascular integrity and heart development (9). To 
determine the in vivo role of the mammalian MEF2 transcription factor, global deletion of MEF2A 
showed that the majority of MEF2A mutant mice die suddenly in the initial perinatal period with 
cardiac enlargement (10). Deleted MEF2A in cardiomyocytes also revealed severe myofibrillar 
defects causing the misregulation of a MEF2A-dependent costamere gene program (11). 
Neonatal cardiomyocytes depleted MEF2A also indicate widespread apoptosis probably resulting 
from deficiencies in focal adhesion contacts (3).  Furthermore, dysregulated expression of MEF2A 
has been reported in the embryonic heart of a cardiac-specific knockout of focal adhesion kinase, 
FAK and cause thin ventricular walls, disorganized myofibrils, and decreased cardiomyocyte 
proliferation (12). Further, previous studies indicated that MEF2A knockdown in zebrafish causes 
cardiac morphology defects, impairments of sarcomere assembly and cardiac contractility. In 
addition, expression of cardiac contractile genes, including troponin C, troponin T, atrial myosin 
heavy chain (aMHC) and cardiac myosin light chain 2 (MLC2,) which are expressed in the cardiac 
contractile organization were down-regulated in absence of MEF2A transcription factor (9).  
Taken together, MEF2A plays important roles in a focal adhesion/costamere regulatory circuit in 
cardiomyocyte differentiation and mediates survival and control of cell growth in cardiomyocytes 
(3).  MEF2C plays an important role in embryogenesis and myogenesis of cardiovascular cells. Of 
the mammalian mef2 genes, depleted MEF2C causes embryonic lethality and displays defective 
cardiac looping morphogenesis and vascular malformation, however, MEF2B expression was 
enhanced, possibly to compensate for the loss of MEF2C (13). Lack of Mef2d resulted in viable 
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mice with normal cardiac function, however, when they were subjected to stress, these hearts 
displayed attenuated hypertrophy and fibrosis (9). Acute depletion of MEF2D in cardiomyocytes 
cells result in cell cycle re-entry programmed cell death (3). Studies also showed that MEF2D has 
two alternative spliced isoforms, α1 and α2, are expressed in skeletal muscle, but the MEF2D α2 
isoform appears to be required for differentiation and includes a coding exon that is resistant to 
inhibitory phosphorylation mediated by protein kinase A (PKA). MEF2B is highly expressed in 
cardiac precursors and primitive heart tube, however, MEF2B knock out mice are viable and its 
absence in heart could be compensated by either MEF2A or MEF2C in cardiac development (13). 
2.4 Regulation of MEF2 activity by post-translational modification 
2.4.1 MEF2 functions as a transcriptional co-factor 
 The MEF2 transcription factor can interact with a diverse array of co-factors that regulate 
MEF2 activity as an activator or as a repressor, depending on co-factor interactions to facilitate 
the ability of MEF2 to respond to intracellular signaling. MEF2 function as a transcriptional co-
factor was first recognized in skeletal muscle, where MEF2 proteins were shown to function as 
essential co-factors for the myogenic proteins, including Myod and myogenin (14). 
Myogenic bHLH proteins have the ability to convert non-muscle cells to muscle cells in 
culture and it was identified that this activity relied on interaction with MEF2. MEF2 and MyoD 
physically associate and their binding sites are coordinately positioned in the enhancers and 
promoters of muscle-specific genes (15). In the heart, MEF2C cooperatively activates 
transcription of the Nppa gene with the bHLH proteins HAND1 and HAND2, which like MEF2, are 
necessary modulators of cardiac development (16). GATA4 is another cardiac transcription factor 
that interacts with MEF2 to activate the nppa promoter. Given the broad overlap in the 
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expression of GATA4 and MEF2 transcription factors and the prevalence of GATA4 and MEF2 sites 
in cardiac promoters, these members of these two families of transcription factors might 
participate in the co-activation of numerous other genes in the heart (17). Thyroid hormone 
receptor (TR) is another MEF2 co-factor that interacts with MEF2 in the heart and this interaction 
is facilitated by another factor called p300/CBP, which is considered to bridge the two factors 
and promote transcriptional activation (18). TR and MEF2 interaction have been recognized to 
be crucial for the activation of the α-mhc gene via closely-positioned binding sites for the two 
factors in the proximal promoter region. Interestingly, the interaction of MEF2 and MyoD in 
skeletal muscle is also facilitated by P300. In details, P300 acetylated MEF2 and subsequently 
cause chromatin relaxation and promote MEF2 transactivation (19). 
2.4.2 MEF2 and chromatin remodeling 
 In the heart, MEF2 activity is regulated by associating with histone acetylase (HATs) and 
deacetylase (HDACs) as chromatin remodeling enzymes which bind to MEF2 and cause chromatin 
relaxation with transcriptional activation and chromatin condensation with transcriptional 
repression (20). In this context, MEF2 forms a complex with class II histone deacetylases (HDACs), 
which include HDACs 4, 5, 6, 7, and 9. Interaction with class II HDACs occurs through the MADS 
domain at the N-terminus of MEF2 and similarly, a conserved N-terminal domain in HDAC 
dictates interaction with MEF2. This complex can repress transcription by deacetylating histones, 
resulting in chromatin condensation and reduced accessibility of core-transcriptional machinery 
to promoter and enhancer regions of MEF2 target genes (21). 
Class II HDACs are prominent mediators of transcription in the developing and postnatal 
heart that help regulate the hypertrophic response. Normal growth of the myocardium needs 
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large amounts of structural proteins to be synthesized as cells enlarge, however excessive 
enlargement of the heart can lead to pathologic hypertrophy, which ultimately causes heart 
failure. Thus, HDACs serve as a kind of regulated braking mechanism, keeping the MEF2-
dependent transcriptional response in check until signals stimulating myocardial growth are 
received.  MEF2 also interacts with several histone acetyltransferases, including P300, which 
serve to balance the repressive effects of HDAC on MEF2 and allow MEF2 to function as a 
transcriptional switch (3).   
 
 
 
 
Figure 2. MEF2 functions as a signal dependent transcriptional switch. MEF2 functions as a 
repressor by recruiting class II HDACs to promoter and enhancer regions of target genes. In 
response to a variety of developmental and pathological signals, CaMK signaling is activated. 
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Phosphorylation of HDAC results in association with 14-3-3 protein and nuclear export. MEF2 
associates with HATs (p300) and potent co-activators.  
 
2.4.3 MEF2 regulation upon signaling pathways in cardiac cells 
 MEF2 transcriptional regulatory machinery plays a crucial function in cardiac gene 
expression during physiological and pathologic adaption of the heart (22). MEF2 is involved in 
activating many genetic programs such as those that control and regulate cell morphogenesis, 
proliferation, differentiation, survival, and apoptosis. These different roles for MEF2 
transcriptional activity are regulated by chromatin remodeling enzymes and several kinase 
signaling cascades. They control MEF2 functions as both a repressor and an activator, depending 
on the gene, cell type and cellular differentiation state to control of physiology and pathology of 
the heart.   
The interaction of MEF2 with HDACs as one type of chromatin remodeling enzyme, 
emphasizes the function of MEF2 proteins as both positive and negative regulators of 
transcription. Furthermore, Class II HDACs are phosphorylated in response to a variety of 
extracellular signals, including pressure and adrenergic signaling. These signals can result in an 
increase in the concentration of Ca2+ in the cytoplasm, which activates the phosphatase 
calcineurin and stimulates the activity of calcium/-calmodulin-dependent kinases (CaMK). 
Phosphorylation of class II HDACs by CaMK happens on the N-terminus of the HDAC protein and 
subsequently, CaMK causes the disruption of MEF2-HDAC complexes upon mediating nuclear 
export of the transcriptional repressor, HDAC II, which binds to 14-3-3 proteins. This interaction 
allows MEF2 to associate with histone acetylases (HATs) and to activate downstream genes (23).  
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MEF2 factors themselves are considerably phosphorylated in response to a host of intracellular 
cues. The P38 and BMK1/ERK5 mitogen-activated protein kinases (MAPK) can phosphorylate 
MEF2 and play a role in MEF2 regulation (24). ERK5 signaling was found to associate with MEF2 
through N-terminal region, which contains the MADS-MEF2 domain and not the C-terminal 
domain that P38 binds (25). ERK5 phosphorylates MEF2C at serine-387 which is a conserved 
residue in MEF2A and MEF2C, but not in MEF2B or MEF2D in response to a variety of extracellular 
signals, including adrenergic signaling and pressure overload in the myocardium (26). The p38 
MAPK signaling pathway also plays a crucial role in the post-translational modification of MEF2 
in myocytes. In fact, p38 can directly phosphorylate MEF2A and MEF2C and enhance its 
transcriptional activity, but not MEF2B and MEF2D. The p38 phosphorylation promotes the role 
of MEF2 as a transcriptional activator in response to normal developmental and postnatal 
hypertrophic growth of the heart, as well as to pathologic hypertrophic cue (25,27). 
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Figure 3. MEF2 regulation by signaling pathways.  Calcium-dependent signals activate MEF2 by 
stimulating calcium-calmodulin dependent kinases (CaMK) and calcineurin. MAP kinases 
signaling and the subfamilies include the extracellular regulated kinase 5 (ERK5) and the p38 
MAPK can activate MEF2.  
3. Myocardial remodeling 
 Myocardial remodeling is a process by which ventricular size, shape, and function are 
regulated by mechanical, neuro-hormonal, and genetic factors. In this context, cardiac 
remodeling might be physiological during normal growth or maladaptive due to pressure 
overload, volume overload, hypertrophy, cardiomyopathy, hypertension, myocardial infarction 
or valvular heart disease (28). Left ventricular remodeling is also a step on the progression to 
heart failure, refers to the acute loss of myocardium which results in an abrupt increase in loading 
conditions that induce the infarcted border zone and remote non-infarcted myocardium. The 
underlying molecular and cellular processes leading to cardiac remodeling consist of myocyte 
growth (cardiac enlargement/cardiac hypertrophy), myocyte death, and remodeling of the extra-
cellular matrix (ECM) (29).  
3.1 Cardiac Hypertrophy 
 Cardiac hypertrophy refers to the abnormal enlargement, or thickening of the heart 
muscle resulting from an increase in cardiomyocyte size and changes in heart muscle 
components, such as enhancing protein synthesis, and re-organization of sarcomeres (30). 
Cardiac hypertrophy has two forms; physiological and pathological hypertrophy. Physiological 
hypertrophy happens during normal growth. The size of chamber and thickness of the wall grow 
in response to natural reactions, such as pregnancy and exercises.  In physiological hypertrophy, 
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cardiomyocytes are increased in the length and width and eventually lead to ventricular 
hypertrophy with enhanced cardiac performance, however, there is no cardiac dysfunction, 
fibrosis, and heart failure (31) (32). In pathological cardiac hypertrophy, cardiomyocytes initially 
undergo compensatory hypertrophy which is an adaptive response to pressure or volume 
overload, however, they eventually increase in size with a significant thickening of the ventricular 
walls and lose their elasticity in long standing of cardiomyocyte hypertrophy during development 
and deterioration of heart failure (28). Pathological hypertrophy commonly happens as a result 
of myocardial infarction, hypertension, and myocardial valve diseases. According to cellular and 
molecular level, it is characterized by sarcomere re-organization, activation of transcriptional 
machinery, re-expression of immediate early genes, such as (c-jun, c-fos), enhanced protein 
synthesis and increased expression of cardiac fetal genes such as β myosin heavy chain (β-MHC) 
and atrial natriuretic factor (ANF) (2). There are two different pathological hypertrophy 
phenotype, concentric hypertrophy, and eccentric hypertrophy. Concentric hypertrophy caused 
by pressure overload in conditions such as hypertension.  Sarcomeres are added in parallel and 
growing in lateral. The size of the chamber goes down, however, the thickness of the wall goes 
up. In contrast, eccentric hypertrophy caused by volume overload in conditions such as 
myocardial infarction, cardiac dilation, and cardiomyopathy. Sarcomeres are added in series and 
growing in longitudinal. The thickness of the wall goes down, however, the size of the chamber 
goes up (Hunter et al. 1999) (33).   
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Figure 4. Different types of cardiac hypertrophy. The normal heart can develop various types of 
cardiac remodeling depending on the stress. Physiological hypertrophy caused from natural 
actions, such as exercises and pregnancy, in which individual cardiomyocytes increase in length 
and width and the heart stands a balanced type of eccentric hypertrophy (Chamber walls, and 
septum enlarge in size). Pathological cardiac hypertrophy caused by pathologic stress and 
neuroendocrine factors which lead to concentric hypertrophy, in which cardiomyocytes increase 
in width compared with length, resulting in the wall and septal thickening and a loss of chamber 
area. However, long-standing of this state can deteriorate into eccentric hypertrophy, in which 
cardiomyocytes reduce in width and lengthening, leading to extreme chamber enlargement with 
loss of wall and septal thickness. 
 
3.2 Signaling pathway in cardiac hypertrophy           
 Pathological cardiac hypertrophy characterized by abnormal growth of cardiac myocyte 
upon re-organization of the sarcomeres and activation of fetal cardiac genes (32). At the 
molecular level, these effects lead to activation of intracellular signaling pathways that ultimately 
regulate pathological gene expression programs. Briefly, signaling pathways involved in cardiac 
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hypertrophy include G-protein coupled receptor, mitogen-activated protein kinase (MAPK), 
protein kinase A (PKA) and C (PKC) signaling, Ca2+ dependent pathways; calmodulin-dependent 
kinase (CaMK), and calcineurin. (34) (31). 
3.2.1 Myocardial G-protein-coupled receptors (GPCRs) 
 Myocardial G-protein-coupled receptors (GPCRs), including adrenergic, angiotensin and 
endothelin (ET-1) receptors mediate a prominent role in the regulation of cardiac function and 
hypertrophic growth (35). GPCRs are coupled to three classes of heterotrimeric GTP-binding 
proteins; Gs, Gq/G11, and Gi which transduce agonist-induced signals to intracellular effectors 
such as enzymes and ion channels. Gq/11- coupled receptors are stimulated through interaction 
with pathological cardiac hypertrophy agonists, such as angiotensin II (AngII), endothelin I (ET-1), 
and α-adrenergic which activates phospholipase C (PLC), and downstream kinase PKC, and 
develop concentric cardiac hypertrophy (31). Stimulating of the β-adrenergic receptors (βAR) 
activates Gαs and adenylate cyclase (AC) activity. Accumulation of cAMP and the subsequent 
activation of PKA lead to phosphorylation of downstream effectors that govern the cardiac 
contraction pathway and thus regulating chronotropy (heart rate) and inotropy (cardiac 
contractility) (36). Acute stimulation of βAR in response to epinephrine and norepinephrine is 
correlated with physiological hypertrophy and increased contractile function but chronic 
stimulation of βAR eventually results in cardiomyocyte hypertrophy, fibrosis, and progressive 
deterioration of cardiac performance (31). We have three different β-adrenergic subtypes, 
including β1, β2, and β3 in mammalian. Β1-Adrenergic receptor is highly expressed in cardiac tissue 
and plays an important role to control of heart rate and contraction. The β2-Adrenergic receptor 
is predominantly expressed in the smooth muscle tissue and acts as a crucial factor to control 
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vasodilatory response. The last subtype, β3-Adrenergic receptor is mainly expressed in adipose 
tissue (37) (Brum et al. 2006). In the heart, β1 adrenergic receptors are the most abundant 
adrenergic receptors and its downstream effector initially increases contractile function but 
eventually results in cardiomyocyte hypertrophy, fibrosis, and progressive deterioration of 
cardiac performance (38). In normal condition, β1-ARs are activated in response to sympathetic 
activation, such as norepinephrine and play an important role to increase chronotropy and 
inotropy. Acute activation of β1-ARs causes to increase cardiac output (CO) during the 
sympathetic response, however, chronic stimulation of the β1-ARs is cytotoxic and leads to 
myocyte death and eventually eccentric cardiac remodeling (37).  
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Figure 5. MEF2 and its regulation by GPCRs (β-Adrenergic Receptor). In acute activation of β-
adrenergic signaling, MEF2 is repressed by activation of PKA. Chronic activation of β-adrenergic 
signaling leads to the activation of CaMKII and nuclear exclusion of HDAC which results in 
enhancing the activity of MEF2 inside the nucleus.   
 
3.2.2 Ca2+ / Calcineurin/ Nuclear Factor of Activated T cells (NFAT) and Ca2+/calmodulin-
dependent protein kinase II (CaMKII) 
 In cardiac hypertrophy, an increase in intracellular Ca2+ concentration can activate many 
Ca2+-dependent signaling pathways which are involved in the progression of the heart failure. 
Calcineurin, a Ca2+/-calmodulin (CaM)-activated phosphatase is one of them. Calcineurin is a 
protein phosphatase that dephosphorylates the nuclear activated T cells (NFAT) transcription 
factor, which leads to its translocation to the nucleus to regulate genes which are involved in 
pathological cardiac hypertrophy and heart failure (39). Ca2+ /-calmodulin-dependent protein 
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kinase II (CaMKII) is another protein which phosphorylates HDAC. Class II HDAC is dissociated 
from MEF2. MEF2 transcriptional activity is enhanced inside the nucleus and mediate progression 
of cardiac hypertrophy genes (30).  
3.2.3 Myocyte Enhancer Factor-2 (MEF2)/ Histone Deacetylases (HDACs) 
 MEF2 activity can be regulated by direct association with histone acetylates (HATs) and 
deacetylates (HDACs) which are chromatin remodeling enzymes. These enzymes are recruited to 
the target genes through binding to particular transcription factors such as MEF2. In details, HATs 
acetylate nucleosomal histones and leads to chromatin relaxation and transcriptional activation, 
however, HDAC does the reverse work and causes chromatin condensation and repression of the 
transcriptional activation. In response to cardiac hypertrophy, phosphorylation of class II HDACs 
by CaMKII disrupts the complex of HDAC and MEF2 and it leads to exposure of a nuclear export 
of HDAC through recruiting with 14.3.3 protein and activation of MEF2 transcriptional activity 
contributed to the genes observed in cardiac failure (3). 
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Statement of purpose 
 Our group previously showed that Myocyte enhancer factor 2 (MEF2) has a prominent 
pro-survival role in cardiomyocytes and this property can be regulated through β-Adrenergic / 
PKA signaling (40).  
Although MEF2 proteins are important transcription factors to regulate the expression of 
genes in the physiological and pathological adaption of the heart, there is a lack of information 
about protein-protein interaction and post-translational modifications of MEF2. These 
interactions may regulate hypertrophic gene transcription in response to activating β-adrenergic 
signaling. We speculate that studying the regulation of MEF2 interactome in cardiomyocytes may 
develop the approaches to recognize MEF2 as an activator or a repressor to regulate survival and 
hypertrophy gene transcriptions. Our work developed the strategies to study and uncover MEF2 
interactome in HL-1 cardiomyocytes for the next step, using quantitative proteomics approaches. 
In our work we also mimicked an experimental hypertrophy condition using isoproterenol 
treatment through acute activating of β-adrenergic receptors in HL-1 cardiomyocytes.  
 In previous research, transcriptome analysis (RNA-seq) from left ventricular RNA samples 
and MEF2A depleted cardiomyocytes identified some genes, including klf2, junb, alas2 and 
rarres2 which may have implications in cardiac hypertrophy (41). Our ChIP-qPCR result indicated 
that MEF2A is recruited to the rarres2 promoter in primary cardiomyocytes. Thus, rarres2 is a 
novel MEF2A target gene and it will be interesting to study rarres2 gene regulation by MEF2A 
interactome characterization.   
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Rationale of study 
 Cardiomyocytes are terminally differentiated cells of the myocardium that lose their 
ability to proliferate after birth. Thus, they grow in cell size without cell division to adapt to a 
demand for increased workload of the heart. In this context, cardiac transcription factors are 
defined as transcriptional activators which are expressed predominantly in the myocardium. 
They regulate the expression of the cardiac genes encoding structural proteins which are central 
to cell growth, regulate of survival, and differentiation. MEF2 is one of the most prominent 
cardiac transcription factors which controls cardiac muscle differentiation, heart development, 
and vascular integrity. In previous research, our group identified that MEF2 activity is repressed 
upon acute activation of β-adrenergic/ PKA signaling pathway. β-blockade treatment upregulates 
MEF2 activity and promoting a pro-survival function of MEF2 in cardiac myocytes (40). Previous 
studies also identified that MEF2 transcription factors are associated with the regulation of genes 
expressed during cardiac hypertrophy. We suspect that changes in MEF2 activity may be caused 
by alterations in protein-protein interaction and post-translational modifications. These 
interactions may regulate hypertrophic gene transcription in response to activating β-adrenergic 
signaling.  
To study the regulation of MEF2A interactome in cardiomyocytes, we chose HL-1 cardiac 
muscle cells for the model of study. HL-1 cardiac muscle cell line is an immortalized mouse 
cardiomyocyte cell line derived from an AT-1 mouse atrial cardiomyocyte tumor. They can be 
serially passaged unlike neonatal primary cardiomyocytes, they maintain the ability to contract 
and retain differentiated cardiac morphological, biochemical, and electrophysiological properties 
(42).  
20 
 
The rationale for choosing MEF2A was that it is predominantly expressed in the adult 
heart and forms heterodimers with MEF2D. It also targets genes which may be involved in 
survival and control of cell growth. Previous research also revealed that depleted MEF2A is 
associated with severe myofibrillar defects and cardiac enlargement which may regulate many 
hypertrophy genes. To study regulation of MEF2A interactome in cardiomyocytes, first we 
optimized two different methods for immunoprecipitation (IP) of MEF2A interacting proteins 
(interactome), IP of endogenous MEF2A interactome proteins and immunoprecipitation of Flag-
MEF2A interactome proteins.  Induction of cardiac hypertrophy in cardiac HL-1 muscle cells have 
been done with an agonist (isoproterenol). Isoproterenol binds to GPCRs and causes activation 
of β-adrenergic / PKA signaling pathway in cardiomyocytes. Hypertrophy in cardiomyocytes 
observed by visualizing and quantitating the cell surface area of cells as an index of cellular 
hypertrophy upon wheat germ agglutinin (WGA) staining. Taken together, we developed two 
systems to precipitate MEF2A interactome in normal and hypertrophy conditions. Besides, we 
established our in-vitro model under experimental hypertrophy condition by isoproterenol 
treatment. These experimental achievements will allow state of the art quantitative proteomics 
approaches to study MEF2A interactome in both normal and hypertrophy conditions.  
The previous study, transcriptome analysis (RNA-seq) from left ventricular RNA samples 
and MEF2A depleted cardiomyocytes identified 65 differentially expressed genes (DEGs) upon 
transverse aortic constriction (TAC) treatment. Of the 65 TAC regulated DEGs, atenolol (AT) 
reversed the expression of the 28 mRNAs. Some of them, including klf2, junb, alas2, and rarres2 
are selected for further analysis. The rationale for choosing these particular genes was that they 
were dysregulated under TAC conditions and, prominently, their expression pattern was 
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substantially reversed with Atenolol treatment. Thus, they may be involved in pathological 
hypertrophy that can be potentially changed by drug therapy (41). Since two fundamental 
features of heart failure are cardiomyocyte hypertrophy and apoptosis, we attempted to further 
test the capacity of some of the identified genes in vitro using gain and loss of function analysis. 
For the gain of function (GOF) analysis, we tested exogenously klf2, junb, and alas2 alone and in 
combination to assess their effects on induction of hypertrophy by visualizing and quantitating 
the cell surface area as an index of cellular hypertrophy in HL-1 cardiac muscle cells (41). 
We also identified that rarres2 is a novel MEF2 target gene which MEF2A is recruited to 
the rarres2 promoter in primary cardiomyocytes. This result provides us with an opportunity to 
further study gene regulation of rarres2 by some characterized MEF2A interactome in cardiac 
diseases. Previous studies revealed that rarres2 gene may affect CASPASE 9 and promote cardiac 
apoptosis in cardiomyocytes. We speculated that rarres2 gene may also play a role to develop 
cardiomyocytes hypertrophy. Thus, we tested the potential role of rarres2 gene to promote 
cardiac hypertrophy in primary neonatal cardiomyocytes and HL-1 cardiac cells. Our result 
showed that cross-sectional area of only transfected cells with exogenous expression of Rarres2 
is significantly enhanced compared to that of in control condition. Thus, rarres2 highly likely plays 
an important role to promote cardiomyocyte hypertrophy. Overall, we studied the potential role 
of some genes including rarres2 gene to develop cardiac hypertrophy in the HL-1 cardiac cell, 
however, our observations show that further analysis needs to be done to study MEF2A 
regulation of rarres2 gene in heart disease. 
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Materials and Methods 
 
Cell Culture 
 
A) Primary neonatal rat cardiomyocytes 
 
Neonatal rat cardiomyocytes prepared from 1 to 3 days old Sprague Dawley rats using the 
Neonatal Cardiomyocyte Isolation system (Worthington Biochemical Corp, Lakewood, NJ, 
USA). Briefly, whole hearts (8-12) were dissociated with trypsin (Promega, Madison, WI, 
USA) and collagenase (Worthington Biochemical Corp). The cells were re-suspended in 
Dulbecco’s Modified Eagle’s medium F12 (Gibco, Burlington, ON, Canada) supplemented 
with 10 % fetal bovine serum, 1% penicillin/streptomycin and 50 mg/l gentamycin sulfate 
(Invitrogen, Burlington, ON, Canada). The isolated cells were plated for 60 min in 37 °C 
humidified incubator with a 5% CO2 in air, allowing differential attachment of non-
myocardial cells. The cardiomyocytes were counted and transferred to gelatin-coated 
plates. The following day, the culture media was removed and replaced with fresh media. 
For drug treatment and transfection, cells were serum starved for the indicated time and 
replenished with fresh medium every 24 hours.  
B) HL-1 Cardiac muscle cell line 
The HL-1 cell line was originally established from an AT-1 subcutaneous tumor from an 
adult female Jackson Laboratory inbred C57BLY6J mouse. HL-1 Cardiac cells were cultured 
by Clay-comb medium (Sigma) including; 10 % fetal bovine serum, 100 μM nor-
epinephrine (Sigma), 100 μg/ml Hyclone penicillin-streptomycin in 70-% confluency 
plates. In detail, to prepare 100 ml supplemented Claycomb Medium, we added 87 ml 
Claycomb Medium, 10 ml 10% fetal bovine serum (FBS), 1 ml 100 μg/ml Hyclone penicillin-
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streptomycin, 1 ml 0.1 mM norepinephrine (10 mM stock), and 1 ml 2 mM L-glutamine 
(200 mM stock).  
Freezing Medium 
Freezing medium is made up of 95% FBS/5% DMSO. This can be stored up to a week at 4 
°C. 
Pre-Coating Flasks (Gelatin/Fibronectin) 
Gelatin (0.1 g) was dissolved in 500 ml distilled water and autoclaved. The concentration 
of the gelatin was 0.02%. Fibronectin (1mg/ml) is received in a tube as a liquid and 1 ml 
fibronectin was diluted in 199 ml of 0.02% gelatin. Before culturing cells, tissue culture 
plates were coated with gelatin/fibronectin and incubated at 37 °C for at least one hour. 
The gelatin/fibronectin was removed by aspiration just before adding the cells to the 
plates. 
Culturing Cells 
Cultures were fed with supplemented Claycomb Medium every weekday. To avoid 
feeding the cells on weekends, 10 ml of supplemented Claycomb Medium was added to 
each plate Friday afternoon; the Medium is not changed until the following Monday 
morning. 
Passaging- Procedure for a 1:3 Split 
When the cells in the remaining plates reached confluency three days later, they were 
split 1:3.  
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Treatment with isoproterenol 
HL-1 cells were cultured upon Clay-comb media under serum starvation condition and 
were treated with 10 μM isoproterenol for 72 hours.  
Transformation 
Stock expression plasmids were diluted to 10 ng/μl and stored at -20°C freezer for later 
transformation or 1 μl (10 ng) of expression plasmid was added to 50 μl of E. coli XL1Blue 
and incubated on ice for 30 minutes. Heat shock was performed for 1 min at 42°C water 
bath follows up with 2 min on ice. At the end, the complex was added to the agar plate 
and incubated at 37 °C degrees overnight.  
Western Blot 
             Plastic cell scrapers were used to collect cells on ice in 1X PBS. NP-40 lysis buffer 
containing 150 mM NaCl, 1 mM EDTA, 50 mM Tris-HCL pH 8.0, 1 mM sodium vanadate, 1 
mM PMSF, 0.5 % deoxycholate, supplemented with a protease inhibitor cocktail (Sigma, 
P-8340) was used for biochemical lysis. Protein concentration was determined by 
standard Bradford assay. Equal amounts of proteins were loaded on 10 % SDS-PAGE 
gels. Subsequently, the electrophoretic transfer was done on Immobilon-P membranes 
(Millipore). Blocking was done for 1-2 hours in 5% milk in PBS or TBS dependings on the 
antibody procedures. Next, primary antibody in 1% milk in PBS or TBS-T was incubated at 
4°C overnight. HRP-conjugated secondary antibodies in 1% milk in PBS or TBS were 
incubated at room temperature for 1 hour (Santa Cruz Biotechnology, Cell Signaling 
Technology). Enhanced chemiluminescence reagent (Amersham) was used to detect 
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immuno-reactive secondary antibodies which still bound to the membrane. The 
membrane were then exposed to Biomax film (Kodak).  
Harvesting Cells 
The old media was aspirated and replaced with 1x PBS cold for washing. After aspirating 
the last PBS wash, 1.0 mL of cold 1x PBS was added to cells for scrapping with a rubber 
policeman and transferred to a new tube.  
Protein extraction 
Protein samples were kept on ice during the entire procedure. Cells were washed three 
times with cold 1x PBS. After aspirating the last PBS wash, 1.0 mL of cold 1xPBS was added 
to the cells. Cells were then gently scraped with a rubber policeman and transferred to a 
new tube and then centrifuged at 1500xg for 5 min at 4°C. After removing the PBS, the 
pellet was diluted with three times its volume in NP-40 lysis buffer supplemented with 1 
mM sodium orthovanadate, 1 mM PMSF and protease inhibitor cocktail (Sigma, P-8340).  
 Cells were vortexed briefly every 10 minutes for a total of 30-40 min and 
centrifuged at high speed (>10 000xg) and the supernatant was transferred to a fresh 
tube. Protein concentration was determined by Bradford assay (Bio-Rad) with bovine 
serum albumin (BSA) as a standard. An equal amount of protein was diluted with 3X SDS 
sample buffer and samples were boiled for 5 min chilled on ice and centrifuge to use for 
SDS-PAGE. 
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Transfection  
For transfection in HL-1 cardiomyocytes and primary neonatal rat cardiomyocytes, 
Lipofectamine 2000 (Invitrogen) was employed. Cells were seeded around 80-90 % 
confluence in 10 ml plates or 6-well plates 24 hours prior to transfection. For 6-well plates, 
for each well, dilute a total of 2.5 μg of DNA in 150 μl in Opti-MEM medium (Invitrogen), 
and in a separate tube dilute 2.5X of Lipofectamine 2000 reagent in 150 μl Opti-MEM 
medium. The DNA and Lipofectamine mixtures (300 μl) were combined, mix and 
incubated for a minimum of 5 min at RT. The DNA/Lipofectamine mixture was added to 
the cells in a serum starved culture medium, and incubated at 37 °C overnight. Following 
the incubation, the cells were refed with new medium and allowed to recover for a 
minimum 24 hours prior to harvesting or pharmacological treatment.  
For siRNA knockdown of HL-1 cardiomyocytes, Lipofectamine RNAiMAX (Invitrogen) was 
employed and cells were seeded at 80-90% confluence in 6-well plates for 24 hours prior 
to transfection according to manufacturer’s instruction. For each well, Lipofectamine 
RNAiMAX reagent was diluted into 150 μl in Opti-MEM medium, and in a separate tube, 
siRNA (100 nM) was added to 150 μl Opti-MEM medium. The reagent were mixed and 
incubated for a minimum 5 min at RT. The siRNAiMAX / Lipofectamine mixture was added 
to the cells and incubated at 37 °C overnight. 
Following the incubation, the cell were re-fed with new media and harvested 24 to 48 
hours later for western immunoblotting analysis to determine the efficacy of protein 
knockdown. 
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Reverse Transcription Polymerase Chain Reaction (RT-PCR) 
For primary neonatal cardiomyocytes, total RNA was extracted from cells by using the 
RNeasy plus Kit (Qiagen) and Qiashredder (Qiagen). RNA was converted to cDNA using 
Superscript III (Invitrogen) according to manufacturer’s instruction. 
 
Quantitative Polymerase Chain Reaction (Q-PCR) 
2.5 μl cDNA was mixed with SyberGreen (BioRad) and 500 nM primers in a final volume 
of 20 μl. cDNA was diluted 1:10 before to use. Each sample was prepared in triplicate 
analyzed using Rotor-Gene Q (Qiagen). Parameters for ChIP-qPCR: 5 min 95 °C, [5s 95°C, 
15s 60°C] x 40cycles. Fold change (qRT-PCR) was quantified using the ΔΔCt method.  
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Chromatin Immunoprecipitation (ChIP) 
ChIP experiment was performed followed the guidelines set by EZ ChIP TM with minor 
modifications. The protocol was set up for four possible IPs, 2-4 confluent 10 ml plates 
were used to collect approximately 1 x 10 7 – 5 x 10 7 per each treatment. Confluent plates 
were washed by PBS at RT. Cells were fixed with 1 % formaldehyde (Sigma) for 10-15 min. 
Fixing was quenched by adding 1.25 M glycine (10X Glycine) dropwise to each plate for a 
final concentration of 0.125 M glycine or 1 ml per 10 ml plate for 5 min with slow rocking. 
Plates were placed on the ice and washed with ice-cold 3x PBS. Cells were scraped on ice 
into 1 ml of ice-cold PBS containing Roche tablet and PMSF (10.5 ml PBS + 1 Roche tablet 
+ 105 μl PMSF. Cells were pelleted by centrifugation at 5000 rpm for 5 minutes at 4 
degrees. The supernatant was removed and the subsequent pellet was washed with 1 ml 
of wash buffer I (10 mM HEPES pH 6.5, 0.5 M ethylene glycol tetraacetic acid (EGTA), 10 
mM EDTA, 10 mM EDTA, 0.25% Triton X-100, protease inhibitor cocktail, PMSF) for 5 min 
incubation on ice. Nuclei were collected by centrifugation at 5000 rpm for 5 min at 4°C. 
The supernatant was removed and the nuclei was resuspend in 1 ml of wash buffer 2 (10 
mM HEPES pH 6.5, 0.5 mM EDTA, 200 mM NaCl, protease inhibitor cocktail, PMSF) for 10 
minutes on ice. The nuclei was centrifuge at 3000-5000 rpm for 5 minutes at 4°C, the 
supernatant was removed, and the collected nuclei was lysed with fresh lysis buffer (50 
mM Tris–HCl pH 8.1, 1 mM EDTA, 1% SDS, plus Roche tablet and PMSF). Chromatin was 
sheared to approximately 500 bp fragments using sonicator. Crosslinked sheared 
chromatin was collected following a 15-minute spin at maximum speed and transferred 
to the new tubes. Twenty percent of total sheared chromatin was set aside as input. 
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Sheared crosslinked chromatin was diluted 1:10 with IP dilution buffer (0.01% SDS, 
1.1%Triton-X 100, 1.2 mM EDTA, 16.7 Mm Tris-HCL pH 8.1, 167 mM NaCl) and incubated 
with antibody overnight at 4°C with rocking. Protein G Dynabeads (Invitrogen) also were 
blocked with 20 μg salmon sperm DNA in IP dilution buffer (15 μl of beads + 135 ul IP 
dilution buffer + 20 μg salmon sperm DNA per IP) overnight at 4°C with rocking. Next, 152 
μl of pre-blocked beads were incubated with the IP reaction at 4°C for 1h. Dynabeads-
bound antibody-chromatin complexes were washed using IP wash buffer I (20 mM Tris 
pH 8.1, 2 mM EDTA, 500 mM NaCl, 1% Triton-X 100, 0.1% SDS) and then with wash buffer 
II (20 mM Tris pH 8.1, 2 mM EDTA, 500 mM NaCl, 1% Triton X-100, 0.1% SDS), for 10 
minutes incubation at 4°C, and followed with two more washes in Tris-EDTA (TE) buffer 
at 4°C. DNA-protein complexes were separated from the Dynabeads through adding the 
elution buffer (0.1 M NaHCO3, 1% SDS) for 30 minutes incubation at RT. To separate 
protein from DNA, samples were treated with 12 μl of 5 M NaCl (BioShop) at 65°C for 4 h 
or overnight. Protein was further degraded using of Proteinase K (Sigma), EDTA, Tris Ph 
6.5 FOR 1 h at 45°C, and DNA samples were purified using a PCR clean up kit (Qiagen, 
Mississauga, ON, Canada). 
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Immunoprecipitation (IP) 
HL-1 cells were collected and harvested by using NP-40 lysis buffer including, 100 mM 
Tris-HCL pH 8.3, 150 mM NaCL, 0.5% (v/v) NP-40, 0.5 % deoxycholate (DOC), 1x Protease 
inhibitor cocktail. Protein concentration was measured using Bradford assay. 500 μgr 
protein used for the Immunoprecipitation. Immunoprecipitation was performed using the 
Immuno Cruz Optima kit (Santa Cruz Biotechnology), according to the instructions of the 
manufacture. Beads were washed three times with PBS. Proteins eluted from the beads 
by SDS loading buffer at 100 °C for 5 minutes incubation and run into the 10 % SDS –PAGE 
for separation.  
MyHC Staining  
Primary neonatal rat cardiomyocytes were washed with PBS, pH 7.4 and fixed with 4 % 
formaldehyde for 10 minutes at RT followed by membrane permeabilization by 90 % 
methanol at -20 °C for 10 minutes. The cells were blocked using 5 % milk in PBS for 1 hour 
at 37 °C. Cells were incubated at room temperature with MF-20 (MyHC antibody) diluted 
in blocking buffer (1 % milk PBS) for 2 hours.  Then cells were washed three times with 
PBS and incubated for 60 minutes at room temperature with horseradish peroxidase 
(HRP)-conjugated α-mouse secondary antibody. Cells were again washed three times with 
PBS. Next, cells incubated with the developer which was (0.06 mg/ml DAB and 30% 
hydrogen peroxide in PBS) to detect α-MyHC. In the end, cell incubated for 2 min with 
Haematoxylin and washed. Images were taken with an Olympus CKX41 microscope.  
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Wheat Germ Agglutinin (WGA) staining  
Cells (primary neonatal rat cardiomyocytes and cardiac HL-1 muscle cell line) were fixed 
with 4 % formaldehyde for 15 minutes. Cells were washed three times with cold PBS. 
Attention was made not to permeabilize the cells. Sufficient amount of labeling solution 
(10 μg/ml) was applied to the cells and incubated for 10 minutes at RT. Cells were washed 
three times with cold PBS. Cells were visualized using Alexa Fluor 633 (Invitrogen) 
staining, fluorescence excitation (Ex 632nm) and emission (Em 647nm). Images were 
captured using Axio Observer, Z1 microscope, Plan-Apochromat 63x Oil objective, SDC 
Camera. For GFP, Ex: 488nm and Em: 509nm, DAPI, Ex: 353nm Em: 465nm, and WGA, Ex 
631nm and Em 647nm. Cross-sectional area of cells was quantified using Zen Zeiss 
Microscopy Analysis Program. 
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Results 
 Some of the following experiments were published in Nature Scientific Reports and in this 
manuscript I contributed Fig. 4b, Fig. 6b, and Fig. 6e.  
Immunoprecipitation of endogenous MEF2A 
 To develop the strategy to study the regulation of MEF2A interactome in cardiomyocytes, 
we initially chose to optimize the system using endogenous MEF2A interactome in HL-1 
cardiomyocytes. In this way, the minimum stress entered into the cells and other proteins could 
bind to MEF2A easier. Our result in figure 6 showed that MEF2A precipitated successfully from 
the protein lysate. IgG used as a negative control.  
 
A) 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 6. An immunoprecipitation (IP) assay was performed in HL-1 cells, using MEF2A antibody 
to precipitate MEF2A protein. 10 μg lysate used for the input. 
 
 
 
 
IgG MEF2A Input 
MEF2A 
IP- Eluted protein 
- 72 kDa 
IP: MEF2A 
IB: MEF2A 
- 72 kDa 
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Immunoprecipitation of 3X-Flag-MEF2A in HL-1 cardiomyocytes 
 
 Using a Flag-Tag expression system is another method to develop our strategy to study 
the regulation of MEF2A interactome in cardiomyocytes. The rationale for using this method is 
that it is very small hydrophilic tags which improve detection and purification of the recombinant 
fusion protein. It also facilitates the study of low-abundance protein and the optimization of 
difficult expression protein. However, FLAG-tag fused to our protein which may cause small 
hindrance for the other co-factors to bind to MEF2A from N-terminus. Last but not least, 
scientists believed that over-expression of MEF2A cause to activate protein kinase signaling 
pathways which regulate gene transcriptions involved in cardiac hypertrophy.  
 In this way, first we needed to show that 3X-Flag-MEF2A expression vector could be 
successfully transfected in our model of study. Next, tried to optimize the immunoprecipitation 
method for pulling down 3X-Flag-MEF2A interactome.  
 Our result in figure 7 (A) Indicated that both primary neonatal cardiomyocytes and cardiac 
HL-1 cells were successfully over-expressed with 3X-Flag-MEF2A. Actin was used a loading control 
in the western blot. Figure 7 (B) indicated that immunoprecipitation of 3X-Flag-MEF2A proteins 
has been done successfully in HL-1 cardiac muscle cells.  
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A) 
           
 
 
 
 
 
 
B) 
 
 
 
 
Figure 7. (A) Primary cardiomyocyte and HL-1 cells were over-expressed by 3x-Flag-peptide-
MEF2A through transfection by Lipofectamine 2000. 20 μg protein from the lysate used for the 
conditions in Immuno-blotting. (B) IP assay was performed in HL-1 cells, using Flag antibody to 
precipitate Flag-MEF2A protein. 10 μg lysate used for the input.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
- + - + 
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Flag-MEF2A 
Flag-MEF2A 
ACTIN - 42 kDa 
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IB: Flag AB 
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IB: Flag AB 
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Inducing cardiac hypertrophy in HL-1 cardiac muscle cells by Isoproterenol treatment 
 
 To establish an experimental cardiac hypertrophy condition in HL-1 cardiomyocytes, we 
employed isoproterenol (ISO). Isoproterenol binds to GPCRs and promotes the activation of the 
β-adrenergic/ PKA signaling pathway and causes acute cardiac hypertrophy.  In our experiment, 
10 μM Isoproterenol was added to the media and the cells were treated for 72 hours. Cells were 
fixed after 24, 48, and 72 hours and stained with wheat germ agglutinin (WGA) staining. Cross 
sectional area of cardiomyocytes was visualized and quantitated by Zen Zeiss program. We 
observed that there is a statistically significant enhancement in cell surface area of 
cardiomyocytes which means that it developed a role in promoting cardiomyocytes hypertrophy. 
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Figure 8.  WGA staining depicting cardiac hypertrophy in HL-1 cardiac cells upon 10 μM 
isoproterenol treatment for 72 hours.  Cross sectional area of HL-1 cells quantified based on 10 
cell measurements per image. Scale bar is 20 μm. Data are presented as ± SEM. 
*P ˂ 0.01 vs control. 
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Immunoprecipitation of endogenous MEF2A in cardiomyocyte hypertrophy  
 
 To study the regulation of MEF2A interactome in cardiomyocytes hypertrophy, we 
mimicked an experimental hypertrophy condition in HL-1 cardiac muscle cells using 10 μM ISO 
treatment for 24 hours. Next, cells were harvested and proteins were extracted. Result in Figure 
9 indicated that immunoprecipitation pulled down MEF2A interactome in normal and 
hypertrophy conditions. 
 
 
 
 
 
 
 
 
 
Figure 9. An immunoprecipitation assay was performed in serum starved cardiac HL-1 cells upon 
± 10 μM isoproterenol treatment. MEF2A antibody was employed to precipitate MEF2A proteins.  
10 μg lysate used for the input.  
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 Transcriptome analysis (RNA-seq) from left ventricular RNA samples and MEF2A depleted 
cardiomyocytes in our previous study found some genes, including klf2, junb, and alas2 which 
may have implications in cardiac hypertrophy (41). junb and klf2 were transcription factors while 
alas2 regulated heme synthesis.  
 Other studies shown that these genes may have a potential involvement in cardiac 
remodeling in heart disease and our study attempted to further test the capacity of klf2, junb, 
and alas2 genes to develop cardiac hypertrophy in vitro. 
The role of klf2, junb, and alas2 in cardiomyocyte hypertrophy 
 
 To study cardiomyocyte hypertrophy, we chose to exogenously express klf2, junb, and 
alas2, alone or in combination to measure their effects on induction of hypertrophy in the cardiac 
HL-1 cell line. Cells were transfected with GFP and expression plasmids for our genes of interest 
individually or in combination. Next cells are stained with WGA to visualize and quantitate the 
cell surface area as an index of cellular hypertrophy (figure 10). Only GFP+ cells were quantified 
for this analysis. Our result indicated that klf2, junb, and alas2 may have a role to develop 
cardiomyocytes hypertrophy since their exogenous expression in cultured HL-1 cells led to a 
significant enhancement in cell surface area with klf2, junb, and alas2 alone or in combination of 
together (41).  
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Figure 10. HL-1 cells were transfected with 3 μg DNA in total. WGA staining depicts cardiac 
hypertrophy. Cardiac HL-1 cells (upper panel) were transfected with GFP and Alas2, Junb, or Klf2 
expression plasmids individually or in a mixture and stained with Wheat Germ Agglutinin (WGA) 
in red. The bar graph indicates that cell size of GFP positive HL-1 cells quantified based on 5 cell 
measurements per image. Scale bar is 10 μm. Data are presented as ± SEM. *P ˂ 0.05 **P ˂ 0.01 
vs control. 
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 rarres2 is another gene identified by transcriptome analysis (RNA-seq) from left 
ventricular RNA samples and Mef2a depleted cardiomyocytes. rarres2 encoded Chemerin 
which was an adipokine shown to be associated with cardiac apoptosis and coronary artery 
disease. In our study, rarres2 was identified as a novel MEF2 target gene which may have 
implications in cardiomyocyte hypertrophy (41). 
rarres2 is a novel MEF2A target gene  
 
 Our ChIP-qPCR indicated that MEF2A is recruited to the promoter of rarres2 gene in 
primary neonatal cardiomyocytes. Our finding opened the new window to study MEF2A 
functions on a rarres2 gene regulation.  
 
Figure 11. ChIP-qPCR analysis demonstrated that Mef2a is recruited to the Rarres2 promoter in 
primary neonatal cardiomyocytes. Acta2 was used as a negative control. Data were presented as 
fold enrichment (n = 3, **P ˂ 0.01) 
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The role of rarres2 in cardiomyocytes  
 In subsequent experiment we also assessed the role of rarres2 gene to induce cardiac 
hypertrophy in primary neonatal cardiomyocytes and HL-1 cardiac muscle cells. Rarres2 gene 
were exogenously expressed in two models. Next, cells are stained for WGA staining to visualize 
and quantitate the cell surface area as an index of cellular hypertrophy (Figure 11). Only GFP+ 
cells were quantified for this analysis. Results precisely showed that there is a significant 
enhancement in cell surface area of transfected cardiomyocytes with our gene of interest. Thus, 
rarres2 may play an important role to promote cardiomyocytes hypertrophy (41). 
 
Figure 12. Cardiac HL-1 cells and primary neonatal cardiomyocytes were transfected with GFP 
and rarres2 expression plasmids and stained with WGA in Red. The bar graph indicates cell size 
of GFP positive cells, quantified by 10 cell measurements per image for HL-1 cardiac cells and 5 
cell measurements per image for primary neonatal cardiomyocytes. Scale bar is 10 μm. Data are 
presented as ± SEM. *P ˂ 0.05, **P ˂ 0.01. 
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Discussion  
 
 In consideration of the fact that the human heart has particularly no innate capacity for 
regeneration, the mechanisms of cardiomyocytes cell growth and survival will become more 
important. In this context, MEF2 was recognized as prominent regulator of myocardial gene 
expression, vascular integrity and heart development (9,13). Previous work from our group and 
others showed that the MEF2 family of transcription factors have been implicated in the control 
of gene expression and differentiation in cardiac (14,43), skeletal (44,45), smooth muscle 
differentiation (13,46), neuronal survival and plasticity (47,48), and T cell activation (49).  
 MEF2 family proteins are also extremely responsive to a number of signal transduction 
cascades, and post-translational modulation by covalent modification by PKC (50), ERKS (51,52), 
p38 MAPK (15,50), and PKA which have been proved by our group (7) and others (53,54).  
 Previous work in our group showed that β-AR/ PKA signaling modulated MEF2 function in 
cardiomyocytes (40) and prolonged activation of the β-AR system regulated MEF2 cellular 
localization in cardiomyocytes and resulted in dilated and heart failure (53,54). Our group also 
observed that acute β-AR stimulation regulated inactivation of the pro-survival function of MEF2 
in cardiomyocyte, thereby leading to myocyte cell death (40), however, chronic hyper-activation 
of β-AR stimulation may have led to a PKA mediated phosphorylation of the ryanodine receptors 
that resulted in calcium leakage from sarcoplasmic reticulum (SR) and stimulated the Ca2+ 
signaling which eventually played prominent role in generation of cardiac hypertrophy, 
progression towards heart failure, and marked activation of MEF2 activity (41,55,56).  
 Post-translational modification of MEF2 transcription factor by targeted phosphorylation 
(50), acetylation and deacetylation (57,58) and also protein-protein interaction with other 
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transcription factors such as GATA4 (17), NFAT (59,60), SRF (45,61), and thyroid hormone 
receptors (62) are becoming a regulatory model in the control of gene expression in cardiac and 
skeletal muscle genes.  However, despite considerable understanding of the transcriptional role 
of MEF2 proteins in the activation of cardiac muscle genes, it remains to be determined whether 
protein interaction network between MEF2 and other transcription factors are implicated in the 
generation of cardiac hypertrophy genes towards heart pathology.  
 Previous work showed that acute β-AR stimulation mediated inactivation of the pro-
survival function of MEF2 in cardiomyocyte, however, chronic hyper-activation of β-AR 
stimulation may have led to enhanced activation of MEF2 activity. Besides, loss of MEF2 function 
resulted in up-regulation and down-regulation of many genes which are implicated in 
cardiomyocytes survival, apoptosis induction and cardiac hypertrophy (19,40,41,63).  
 Among MEF2 family members, MEF2A is the predominant subunit expressed in skeletal 
muscle and adult cardiac cells (64). In skeletal muscle, It has been shown that MEF2A regulate 
several genes associated with the actin cytoskeleton (65,66). In cardiac cells, it formed 
heterodimers with MEF2D and mediated diverse functions in the control of cell growth and 
survival (61,67). The transcriptional activation properties of MEF2A is also modulated by different 
post-translational mechanisms including regulation by MAPKs such as p38 (68), ERKs (61,68), and 
PKA (40) and also through interaction with class II HDACs which suppress MEF2-target gene 
activation (69). MEF2A loss of function is also associated with mitochondrial and contractile 
defects (10), sarcomere disorganization, and cardiac enlargement which may regulate many 
hypertrophy genes (3). Taken together, MEF2A functions indicated prominent roles to regulate 
survival and hypertrophy genes in cardiomyocytes.  
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 The spotlight of this project was to study regulation and function of MEF2A in 
cardiomyocytes. Understanding MEF2A protein networks associated with cardiac hypertrophy 
will provide critical insight into underlying role of MEF2A protein interaction in heart disease. 
Thereby, we hypothesized that characterizing the regulation of MEF2A interactome in 
cardiomyocytes may uncover MEF2A functions as an activator or repressor to regulate survival 
and hypertrophy gene transcriptions. This will be achieved using state of the art quantitative 
proteomics approaches.  
 For this project, firstly we developed and optimized two different strategies for pulling 
down MEF2A interactome in cardiomyocytes. The first strategy was endogenous IP of MEF2A 
interactome in HL-1 cardiomyocytes (figure 6). Our endogenous IP concentrated and isolated 
MEF2A interactome in the natural condition successfully. Quantitative proteomics approaches 
will be the next step to characterize our MEF2A interactome in natural condition. We speculate 
that some known MEF2A protein network such as MEF2D, thyroid hormone receptors, HDACs 
and GATA4 were bound to Mef2a and precipitated by IP technique and will be characterized by 
quantitative proteomics techniques. Importantly, we will identify other transcription factors 
which were still unknown and bound to MEF2A and may have prominent role on MEF2A functions 
to regulate Mef2a cardiac survival genes.  
 To study regulation and function of MEF2A interactome in HL-1 cardiomyocytes 
hypertrophy, an experimental hypertrophy condition was mimicked in HL-1 cardiomyocytes 
using isoproterenol treatment to activate β-adrenergic signaling and subsequently concentric 
hypertrophy. Our observation and quantification in figure 8 confirmed the hypertrophy condition 
in our experimental cultured cells. We expect that Mef2 transcriptional activity will be inactive 
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to regulate cardiac survival genes due to acute stimulating of β-adrenergic signaling at the 
beginning stage of the hypertrophy. Thereby, we speculate to precipitate MEF2A protein 
partners which were bound to MEF2A while cardiomyocytes were initially leading to hypertrophy 
condition.    
 A follow up experiment in figure 9 showed that endogenous MEF2A protein could be 
isolated and concentrated in control and hypertrophy conditions using IP method. This is the first 
step which needed to be done to have characterized MEF2A interactome using quantitative 
proteomics techniques. Our precipitated interactome in hypertrophy condition will be assumed 
to have some known proteins bound to MEF2A such as NFAT and p300, however quantitative 
proteomics techniques will characterize the other global MEF2A interactome in hypertrophy and 
natural condition.  We also think that identifying global Mef2a protein network leading to 
understand better MEF2A functions as an activator or repressor on MEF2 survival and 
hypertrophy target genes. 
 In the second strategy, we chose to use Flag-Tag expression system to study regulation of 
MEF2A interactome in cardiomyocytes. The rationale was that FLAG peptide is small hydrophilic 
tags which improves detection and purification of recombinant fusion protein. Pulling down our 
interactome with Flag antibody is more efficient with less non-specific proteins due to using a 
specific Flag antibody. Figure 7 (A) demonstrated that 3X-Flag-MEF2A transfected in primary 
neonatal cardiomyocytes and HL-1 cardiac cells were over expressed successfully. In next step, 
we optimized pulling down of 3X-Flag-MEF2A interactome using IP technique. Our result in figure 
7 (B) showed that 3X-Flag-MEF2A protein was concentrated by IP and observed by western blot. 
However, over-expression of cardiac cells by Flag-MEF2A may activate protein kinase signaling 
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which can mediate expression of cardiac hypertrophy genes (70)(71) and subsequently may alter 
the interactome bound to MEF2A. Furthermore, it will be possible to lose some protein partners 
which could not bind to MEF2A from N-terminal due to having a barrier with Flag peptide which 
was fused to MEF2A from N-terminal.  
 In previous study, our group identified global gene transcription networks associated with 
HF with and without β-blocker treatment. Transcriptome analysis  (RNA-seq) from left ventricular 
RNA samples and MEF2A depleted cardiomyocytes identified some genes, including klf2, junb, 
rarres2 and alas2 which were dysregulated under TAC condition and remarkably, their expression 
pattern was substantially reversed with Atenolol (β-adrenergic receptor antagonist) treatment 
showing that they may be involved in pathological changes that can be potentially altered by 
drug therapy. Two of these genes, junb and klf2 were transcription factors whereas alas2 
mediated heme synthesis and rarres2 encoded Chemerin which was an adipokine.   
 One of the most important features of progressive heart failure is cardiac hypertrophy 
(72) and interestingly, these four genes may be modulated in different aspects of heart failure. 
alas2 was reported to be upregulated and associated with oxidative stress and cell deaths in 
failing human hearts (73). junb was shown as a transcriptional regulator for the upregulation of 
MMP’s which mediated cardiac remodeling in heart disease like ischemia-reperfusion (74). klf2 
has been reported to be involved in endothelial cells by shear stress (75) and has been speculated 
that the upregulation of klf2 correlated with an increased hemodynamic stress . Thus, clearly the 
role of klf2 requires further characterization in cardiac disease. Lastly, rarres2 was shown to be 
associated with cardiac apoptosis and coronary artery disease (76). Taken together, these data 
suggested that these genes may have a potential involvement in cardiac hypertrophy.  
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 We attempted to further test the capacity of Klf2, Junb, and Alas2 genes to develop 
cardiac hypertrophy in vitro.  Cardiac HL-1 cells were co-transfected with GFP and expression 
plasmids for Klf2, Junb, and Alas2 genes individually or in combination and cells were stained 
with WGA to visualize and quantitate the cross-sectional area as an index of cellular hypertrophy. 
Our analysis in figure 10 confirmed that Klf2, Junb, and Alas2 may have a role in promoting 
cardiomyocyte hypertrophy since their exogenous expression in cultured HL-1 cells led to a 
statistically significant enhancement in cell surface area (41). 
 ChIP-qPCR analysis in figure 11 showed that Mef2a is recruited to the rarres2 promoter 
in primary cardiomyocytes. rarres2 is a novel Mef2a target gene (41). We also attempted to 
further test the capacity of rarres2 to develop cardiac hypertrophy in vitro. Primary neonatal 
cardiomyocytes and HL-1 cardiac cells were co-transfected with GFP and Rarres2 expression 
plasmid. Our result in figure 12 indicated that exogenous expression of rarres2 in cultured 
primary neonatal cardiomyocytes and HL-1 cardiac cells led to a statistically significant 
enhancement in cell surface area with rarres2 (41). Our preliminary result concerning the 
possible function of rarres2 gene to promote potential cardiac hypertrophy in cardiomyocytes. 
 These observation supported a cohort of genes with vast potential role on induction of 
cardiac hypertrophy and clearly requires further characterization in a heart context. 
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Future directions 
 Both strategies which were used to pull down MEF2A interactome developed the 
methods for the next step which will be using quantitative proteomics approaches to characterize 
MEF2A interactome in cardiomyocytes. Our knowledge of the mechanisms modulating cardiac 
hypertrophy through MEF2 transcription factor is still incomplete. On the basis of our 
observation, we propose that characterizing MEF2A protein network in normal and hypertrophy 
conditions will fulfil a critical role to understand MEF2A functions as an activator or repressor on 
MEF2 survival and hypertrophy target genes such as rarres2. This achievement may have an 
important implications for our understanding and therapeutic targeting of cardiac pathology.  
 Furthermore, cardiac and skeletal muscle share many properties and are similar in their 
dependence on a sarcomere structure (77). MEF2 is also expressed in both skeletal and cardiac 
muscle cells. Thereby, it can represent a useful paradigm for studying common MEF2A protein 
network and characterize MEF2A functions on common MEF2A target genes in both skeletal and 
cardiac models. 
 MEF2 is a fundamental regulator of cardiac hypertrophy (78) and previous study in our 
group documented the transcriptomic effects of MEF2 suppression in cardiomyocytes (41). From 
those genes, we observed the capacity of klf2, junb, alas2, and rarres2 genes to develop cardiac 
hypertrophy in vitro and found that rarres2 is a MEF2 target gene. The next step will be 
characterizing the functions of those genes with the vast potential for the therapeutic 
interventions in heart failure.   
 We also suggest that characterizing the function of a cohort of MEF2A protein partners 
on regulation of the genes which were dysregulated by TAC and their expression pattern were 
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substantially reversed with drug therapy such as rarres2 will provide a critical insight into the 
underlying etiology of heart failure and unravelling array of molecular targets for therapeutic 
intervention.   
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